{"created":"2025-02-23T06:34:31.784696+00:00","id":2013479,"links":{},"metadata":{"_buckets":{"deposit":"18bea6b8-eb2f-4b20-9c41-8e99f8407f53"},"_deposit":{"created_by":41,"id":"2013479","owners":[41],"pid":{"revision_id":0,"type":"depid","value":"2013479"},"status":"published"},"_oai":{"id":"oai:hiroshima.repo.nii.ac.jp:02013479","sets":["1727147343679:1730442224523:1730442294845"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Effects of N-(4-hydroxyphenyl) Retinamide on Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Prostate Adenocarcinoma Cell Lines","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Tanabe, Tetsuyuki","creatorNameLang":"en"}],"familyNames":[{"familyName":"Tanabe","familyNameLang":"en"}],"givenNames":[{"givenName":"Tetsuyuki","givenNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"Prostate cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"4-HPR","subitem_subject_scheme":"Other"},{"subitem_subject":"uPA","subitem_subject_scheme":"Other"},{"subitem_subject":"PAl-1","subitem_subject_scheme":"Other"},{"subitem_subject":"490","subitem_subject_scheme":"NDC"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Previous investigations have demonstrated that a synthetic retinoid, N-(4-hydroxyphenyl) retinamide (4-HPR), inhibits the invasion of prostate adenocarcinoma in vitro. Urokinase-type plasminogen activator (uPA) is a prerequisite for tumor invasion. The purpose of this study was to evaluate the effects of 4-HPR on uPA and plasminogen activator inhibitor-1 (PAI-1) in prostate cancer.　　    Human prostate adenocacinoma cell lines, TSU-PR1 and PC3, were grown in serum-free media containing 4-HPR. Cellular mRNA and protein were subsequently extracted. Northern blot analysis, enzyme-linked immunosorbent assay (ELISA) and chromogenic functional analysis were performed on the samples.　　    Administration of 10-BM 4-HPR for 3 days resulted in an increase in uPA mRNA expression (TSU-PR1: 391 %, PC3: 356%), and a simultaneous increase in PAI-1 mRNA expression (TSUPR1: 217%, PC3: 235%) was observed. ELISA concomitantly demonstrated a significant increase (p<0.05) in uPA protein in the conditioned media (TSU-PR1: 134%, PC3: 139%) and cell lysates (TSU-PR1: 284%, PC3: 255%). Both cell lines demonstrated a significant increase (p<0.05) in PAI-1 protein in the conditioned media (TSU-PR1: 152%, PC3: 167%) and cell lysates (TSU-PR1: 170%, PC3: 222%). Concentrations below 10-sM failed to alter the protein production of either uPA or P AI-1. The functional uPA assay demonstrated a reduction of the proteolytic activity of uPA (TSU-PR1: 13%, PC3: 7%) in cell lysates of 10-BM 4-HPR (p<0.05), while there was minimal uPA activity in the conditioned media.　　    4-HPR stimulates a paradoxical increase in uPA and PAI-1, but the anti-invasive effects of 4-HPR are consistent with the increase in both uPA and PAI-1, resulting in an overall reduction of functional uPA activities.","subitem_description_language":"en"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"Hiroshima University Medical Press"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"0018-2052","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"AA00664312","subitem_source_identifier_type":"NCID"}]},"item_1617187024783":{"attribute_name":"開始ページ","attribute_value_mlt":[{"subitem_start_page":"67"}]},"item_1617187056579":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2000-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"72","bibliographicPageStart":"67","bibliographicVolumeNumber":"49","bibliographic_titles":[{"bibliographic_title":"Hiroshima Journal of Medical Sciences"},{"bibliographic_title":"Hiroshima Journal of Medical Sciences"}]}]},"item_1617258105262":{"attribute_name":"item_1617258105262","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-03-18"}],"displaytype":"simple","filename":"HiroshimaJMedSci_49_67.pdf","filesize":[{"value":"693.0 KB"}],"mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://hiroshima.repo.nii.ac.jp/record/2013479/files/HiroshimaJMedSci_49_67.pdf"},"version_id":"77a8c709-0bbb-4f65-8db2-1093fef0ce0d"}]},"item_1732771732025":{"attribute_name":"旧ID","attribute_value":"37703"},"item_title":"Effects of N-(4-hydroxyphenyl) Retinamide on Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Prostate Adenocarcinoma Cell Lines","item_type_id":"40003","owner":"41","path":["1730442294845"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-03-18"},"publish_date":"2023-03-18","publish_status":"0","recid":"2013479","relation_version_is_last":true,"title":["Effects of N-(4-hydroxyphenyl) Retinamide on Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Prostate Adenocarcinoma Cell Lines"],"weko_creator_id":"41","weko_shared_id":-1},"updated":"2025-06-02T03:12:32.649925+00:00"}